Biotech Losers: InterMune, Enanta, and GW Pharmaceuticals

In this video from Thursday's Market Checkup, Motley Fool health-care analysts David Williamson and Max Macaluso dive into the biggest stories impacting health-care investors on the market today.

In this segment, a look at the biotech losers on the market during the last two days. InterMune (NASDAQ: ITMN  ) pulled back 10% yesterday, down a total of 22% during the last five trading sessions, as investors remain concerned about new competition for Esbriet, which is the company's idiopathic pulmonary fibrosis drug. Enanta Pharmaceuticals (NASDAQ: ENTA  ) is also down 10%, dragged down by the continuing investor excitement surrounding Gilead and its hepatitis C treatment. Enanta is partners with AbbVie and will get royalties off of AbbVie's own hep. C drug regimen, but investor enthusiasm may be siding with Gilead at the moment. David sees this battle as coming down to relative pricing, and will be watching that closely. And finally, GW Pharmaceuticals (NASDAQ: GWPH  ) fell by 7% after reporting solid earnings that beat on the top line yesterday, after its tremendous run up of more than 500% in the past six months, David sees this as potentially a case of investors taking some profit off the table.

So what's the best way to for investors to play the volatile biotech space?
The best way to play the biotech space is to find companies that shun the status quo and, instead, discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report, "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 10, 2014, at 5:15 PM, siteobserver wrote:

    You're missing a major point on ENANTA - the Enanta/ABBV solution has a 90% CURE rate - as opposed to the "impact" rate for Gilead's oral treatment which is different. It appears that ENTA's solution cures Hep C in patients who do not respond to other treatments. So in addition to price competition, we should watch for signals as to which treatment is more effective - in other words, which is a "cure" and which is a "treatment." The jury is still out on this but the early signals point to Enanta/ABBV. Also, ENTA's stock price tends to down when GILEAD has news, but GILEAD also tends to drop when ENTA has news.

    The next big news on the horizon is ENTA's earnings report - Feb. 24 - followed by results from the phase 3 clinical trials, and later this year, the expected formal approval by the FDA which means ENTA's cure will go on sale this year.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2827990, ~/Articles/ArticleHandler.aspx, 9/16/2014 11:34:08 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement